Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

NCT02914561 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1372

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Filgotinib
OTHER: Placebo

Sponsor

Lakefront Biotherapeutics NV

Collaborators

[object Object]